Brief: SynAct Says CTA Approves For Phase 2B Study Expand
25/08/2022 06:07
Aug 25 (Reuters) - SynAct Pharma AB SYNACT.ST :
* CTA APPROVED FOR THE PHASE 2B STUDY EXPAND
Source text for Eikon: ID:nMFNb31DCq
Further company coverage: SYNACT.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on SynAct Pharma AB
See all newsBrief: SynAct: Shareholding Board, Management Sign Lock-Up Agreements
Sweden's SynAct Pharma posts wider Q1 net loss as expenses rise
Brief: SynAct Pharma Q1 Sales SEK 0
Brief: SynAct Pharma Carries Out Directed Issue Of New Shares
Brief: Synact Pharma Appoints Ann Kristin Led As CFO Effective March 2026